Comparison of Bimatoprost 0.03% and Brimonidine 0.2% in Managing Intraocular Pressure Elevation Following Nd:YAG Laser Capsulotomy for Posterior Capsule Opacification
Background: Posterior capsule opacification (PCO) is the most common cause of vision reduction following successful cataract surgery. It is a dynamic process caused by the migration and proliferation of residual lens epithelial cells on the posterior capsule, leading to visual impairment. The standa...
Saved in:
| Main Authors: | , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wolters Kluwer Medknow Publications
2024-12-01
|
| Series: | Journal of Pharmacy and Bioallied Sciences |
| Subjects: | |
| Online Access: | https://journals.lww.com/10.4103/jpbs.jpbs_605_24 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1841544171009081344 |
|---|---|
| author | Tulika Gupta Rupali Kashyap Shikhar Ganjoo |
| author_facet | Tulika Gupta Rupali Kashyap Shikhar Ganjoo |
| author_sort | Tulika Gupta |
| collection | DOAJ |
| description | Background:
Posterior capsule opacification (PCO) is the most common cause of vision reduction following successful cataract surgery. It is a dynamic process caused by the migration and proliferation of residual lens epithelial cells on the posterior capsule, leading to visual impairment. The standard treatment for PCO is neodymium: yttrium–aluminum–garnet (Nd: YAG) laser capsulotomy. This study aims to compare the efficacy and safety of Bimatoprost 0.03% and Brimonidine 0.2% in preventing intraocular pressure (IOP) elevation post-Nd: YAG laser capsulotomy.
Materials and Methods:
This study was conducted over a year at the Government Medical College, Jammu. 400 patients with PCO post extracapsular cataract extraction were randomly divided into two groups. Group A received 1 drop of Bimatoprost 0.03% and Group B received 1 drop of Brimonidine 0.2%, both administered 1 hour before Nd: YAG laser capsulotomy. Intraocular pressure was measured using Goldmann applanation tonometry before treatment and at intervals of 1 hour, 3 hours, 24 hours, 3 days, and 7 days post-treatment.
Results:
The mean age of patients was approximately 65 years with no significant difference between groups. The baseline IOP was similar across both groups. At 1 hour post-capsulotomy, Group A showed a mean IOP increase of 2.2 mmHg, while Group B showed an increase of 3.6 mmHg. At 24 hours, the IOP in Group A returned to baseline levels, whereas Group B still exhibited a slight elevation. No significant adverse effects were reported in either group.
Conclusion:
Bimatoprost 0.03% is more effective in preventing IOP elevation post Nd: YAG laser capsulotomy compared to Brimonidine 0.2%. It also demonstrated a faster return to baseline IOP levels with fewer side effects. This suggests that Bimatoprost may be a preferable prophylactic treatment for managing post-capsulotomy IOP spikes. |
| format | Article |
| id | doaj-art-e8263b316d07471299e9359b30d48a1b |
| institution | Kabale University |
| issn | 0976-4879 0975-7406 |
| language | English |
| publishDate | 2024-12-01 |
| publisher | Wolters Kluwer Medknow Publications |
| record_format | Article |
| series | Journal of Pharmacy and Bioallied Sciences |
| spelling | doaj-art-e8263b316d07471299e9359b30d48a1b2025-01-12T14:06:34ZengWolters Kluwer Medknow PublicationsJournal of Pharmacy and Bioallied Sciences0976-48790975-74062024-12-0116Suppl 4S3142S314510.4103/jpbs.jpbs_605_24Comparison of Bimatoprost 0.03% and Brimonidine 0.2% in Managing Intraocular Pressure Elevation Following Nd:YAG Laser Capsulotomy for Posterior Capsule OpacificationTulika GuptaRupali KashyapShikhar GanjooBackground: Posterior capsule opacification (PCO) is the most common cause of vision reduction following successful cataract surgery. It is a dynamic process caused by the migration and proliferation of residual lens epithelial cells on the posterior capsule, leading to visual impairment. The standard treatment for PCO is neodymium: yttrium–aluminum–garnet (Nd: YAG) laser capsulotomy. This study aims to compare the efficacy and safety of Bimatoprost 0.03% and Brimonidine 0.2% in preventing intraocular pressure (IOP) elevation post-Nd: YAG laser capsulotomy. Materials and Methods: This study was conducted over a year at the Government Medical College, Jammu. 400 patients with PCO post extracapsular cataract extraction were randomly divided into two groups. Group A received 1 drop of Bimatoprost 0.03% and Group B received 1 drop of Brimonidine 0.2%, both administered 1 hour before Nd: YAG laser capsulotomy. Intraocular pressure was measured using Goldmann applanation tonometry before treatment and at intervals of 1 hour, 3 hours, 24 hours, 3 days, and 7 days post-treatment. Results: The mean age of patients was approximately 65 years with no significant difference between groups. The baseline IOP was similar across both groups. At 1 hour post-capsulotomy, Group A showed a mean IOP increase of 2.2 mmHg, while Group B showed an increase of 3.6 mmHg. At 24 hours, the IOP in Group A returned to baseline levels, whereas Group B still exhibited a slight elevation. No significant adverse effects were reported in either group. Conclusion: Bimatoprost 0.03% is more effective in preventing IOP elevation post Nd: YAG laser capsulotomy compared to Brimonidine 0.2%. It also demonstrated a faster return to baseline IOP levels with fewer side effects. This suggests that Bimatoprost may be a preferable prophylactic treatment for managing post-capsulotomy IOP spikes.https://journals.lww.com/10.4103/jpbs.jpbs_605_24bimatoprostbrimonidinecataract surgeryintraocular pressureiopnd:yag laser capsulotomyocular hypertensionophthalmologypcoposterior capsule opacification |
| spellingShingle | Tulika Gupta Rupali Kashyap Shikhar Ganjoo Comparison of Bimatoprost 0.03% and Brimonidine 0.2% in Managing Intraocular Pressure Elevation Following Nd:YAG Laser Capsulotomy for Posterior Capsule Opacification Journal of Pharmacy and Bioallied Sciences bimatoprost brimonidine cataract surgery intraocular pressure iop nd:yag laser capsulotomy ocular hypertension ophthalmology pco posterior capsule opacification |
| title | Comparison of Bimatoprost 0.03% and Brimonidine 0.2% in Managing Intraocular Pressure Elevation Following Nd:YAG Laser Capsulotomy for Posterior Capsule Opacification |
| title_full | Comparison of Bimatoprost 0.03% and Brimonidine 0.2% in Managing Intraocular Pressure Elevation Following Nd:YAG Laser Capsulotomy for Posterior Capsule Opacification |
| title_fullStr | Comparison of Bimatoprost 0.03% and Brimonidine 0.2% in Managing Intraocular Pressure Elevation Following Nd:YAG Laser Capsulotomy for Posterior Capsule Opacification |
| title_full_unstemmed | Comparison of Bimatoprost 0.03% and Brimonidine 0.2% in Managing Intraocular Pressure Elevation Following Nd:YAG Laser Capsulotomy for Posterior Capsule Opacification |
| title_short | Comparison of Bimatoprost 0.03% and Brimonidine 0.2% in Managing Intraocular Pressure Elevation Following Nd:YAG Laser Capsulotomy for Posterior Capsule Opacification |
| title_sort | comparison of bimatoprost 0 03 and brimonidine 0 2 in managing intraocular pressure elevation following nd yag laser capsulotomy for posterior capsule opacification |
| topic | bimatoprost brimonidine cataract surgery intraocular pressure iop nd:yag laser capsulotomy ocular hypertension ophthalmology pco posterior capsule opacification |
| url | https://journals.lww.com/10.4103/jpbs.jpbs_605_24 |
| work_keys_str_mv | AT tulikagupta comparisonofbimatoprost003andbrimonidine02inmanagingintraocularpressureelevationfollowingndyaglasercapsulotomyforposteriorcapsuleopacification AT rupalikashyap comparisonofbimatoprost003andbrimonidine02inmanagingintraocularpressureelevationfollowingndyaglasercapsulotomyforposteriorcapsuleopacification AT shikharganjoo comparisonofbimatoprost003andbrimonidine02inmanagingintraocularpressureelevationfollowingndyaglasercapsulotomyforposteriorcapsuleopacification |